Screener
Arcus Biosciences RCUS Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Types of securities as of June 30, 2026 | Amortized Cost | Unrealized Gain | Unrealized Loss | Fair Value |
|---|---|---|---|---|
| Money market funds | $138 | — | — | $138 |
| U.S. treasury securities | 222 | — | — | 222 |
| Corporate securities and commercial paper | 407 | — | (1) | 406 |
| Certificate of deposit | 9 | — | — | 9 |
| Total cash, cash equivalents and marketable securities | $776 | — | $(1) | $775 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's cumulative cost basis?
- Arcus Biosciences (RCUS) reported cumulative cost basis of $776M in Q2 2026.
- How has Arcus Biosciences's cumulative cost basis changed year-over-year?
- Arcus Biosciences's cumulative cost basis decreased by 16.3% year-over-year, from $927M to $776M.
- What is the long-term trend for Arcus Biosciences's cumulative cost basis?
- Over 3 years (2022 to 2025), Arcus Biosciences's cumulative cost basis has grown at a -4.1% compound annual growth rate (CAGR), from $1.15B to $1.01B.
- What does cumulative cost basis mean?
- The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.
Ask your AI about Arcus Biosciences's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude